Oral presentation of Ph 1a clinical data highlights potential best-in-class drug profile in heavily pretreated patients with PI3Ka-mutant metastatic breast cancer and other solid tumors Overall, ...
Celcuity recently reported in the Journal of Clinical Oncology that its Phase 3 VIKTORIA-1 trial in PIK3CA wild-type ...
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology ...
In the realm of cellular biology, programmed cell death (PCD) stands as a pivotal process governing the elimination of cells, thereby maintaining tissue homeostasis and ensuring an organism's health ...
Barclays 28th Annual Global Healthcare Conference March 11, 2026 10:30 AM EDTCompany ParticipantsSanjiv Patel - ...
Whitehawk Therapeutics CEO Dave Lennon outlined the company’s strategy and near-term milestones at the Inaugural Life Sciences Conference in Miami, describing a three-program antibody-drug conjugate ( ...
As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) ...
12d
Relay Therapeutics, Inc. (RLAY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
TD Cowen 46th Annual Health Care Conference March 2, 2026 3:10 PM ESTCompany ParticipantsSanjiv Patel - CEO, President ...
Premature ovarian insufficiency (POI) is a clinically significant cause of infertility that affects between 1 to 3% of women ...
A system of five models helps peer reviewers to write more constructive comments, but it is not yet known whether this strengthens the papers that are being reviewed. An artificial-intelligence coach ...
24d
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results